Fulvestrant or capecitabine plus pyrotinib for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult woman (age 18 to 80) with breast cancer that has spread (metastatic) and can’t be cured with surgery or radiation
- Your tumor tests positive for estrogen and/or progesterone (ER/PR) and also positive for HER2
- You must be postmenopausal (or have had both ovaries removed, or stopped ovarian function with medicines)
- Your cancer should have progressed after previous trastuzumab-based treatment, and the last trastuzumab treatment should have ended more than 12 months ago
- You have at least one measurable spot on scans (or a certain type of bone metastasis) that can be followed during the study
- Your blood counts, liver/kidney tests, and heart rhythm/heart pumping ability must be in safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
This trial tests a combination of two oral medications, capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy), for people with HER2-positive breast cancer that has spread and has already been treated with an antibody-drug conjugate (ADC). The goal is to see if this combination can help control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.